Company news
Synact Pharma Ab (OMXSTO:SYNACT) news
Synact Pharma Ab news releases on 6ix. Latest, Sep 22, 2026: SynAct Pharma to Participate in Investor and Partnering Conferences
Press releases & updates
SynAct Pharma to Participate in Investor and Partnering Conferences
September 22, 2026
WHO Identifies Resomelagon as One Of Six Dengue Drug Candidates with Evidence Supporting Further Clinical Development
September 16, 2026
Further Analysis of the Phase 2b ADVANCE Study Reinforces Phase 2b EXPAND Results and Supports Phase 3 Development - FDA Discussions on Trial Design Planned for Q4 2026
September 7, 2026
SynAct Pharma's CEO and CSO Sell Shares
September 3, 2026
SynAct Pharma publishes Q2 2026 interim results
August 20, 2026
SynAct Pharma receives favorable US patent decision for immediate-release resomelagon tablet formulation
August 5, 2026
SynAct Pharma strengthens financial position and strategic flexibility to advance partnering discussions and Phase III readiness
July 20, 2026
SynAct Pharma : Phase 2b ADVANCE study demonstrates positive effects of resomelagon in Rheumatoid Arthritis - supports phase 3 design, regulatory interactions, and partnering
June 15, 2026
Notice of annual general meeting in SynAct Pharma AB
May 7, 2026
SynAct Pharma completes dosing in phase IIb ADVANCE study ahead of June readout
May 6, 2026
SynAct Pharma completes dosing for last patient in Phase 2b ADVANCE study
May 6, 2026
SynAct Pharma publishes Annual Report 2025
April 15, 2026
SynAct Pharma doses first patients in the Phase 2 RESOVIR-2 study with resomelagon
March 26, 2026
SynAct Pharma lays out dual strategy for resolution therapy at capital markets day
March 18, 2026
Invitation to SynAct Pharma’s Capital Markets Day in Stockholm March 11
March 4, 2026
SynAct Pharma: Cash Position Further Strengthened
March 3, 2026
SynAct Pharma secures 51,9 million SEK to strengthen clinical runway
March 3, 2026
SynAct Pharma has carried out a directed issue of new shares of approximately 51.9 MSEK
March 2, 2026
SynAct Pharma announces intention to carry out a directed issue of approximately 45 MSEK
March 2, 2026
SynAct Pharma appoints Ann Kristin Led as Chief Financial Officer
February 24, 2026